Maria T. Petrucci

Rome, 00161, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 184 publications

Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus.

Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus.

Journal: Cancers

Published: June 25, 2026

Association Between Socioeconomic Inequalities and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma.

Association Between Socioeconomic Inequalities and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma.

Journal: JCO oncology practice

Published: May 27, 2026

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 27, 2026

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.

Journal: British journal of haematology

Published: April 26, 2026

Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies.

Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies.

Journal: Frontiers in oncology

Published: November 28, 2025

Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy : Correction to: annals of hematology.

Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy : Correction to: annals of hematology.

Journal: Annals of hematology

Published: November 12, 2025

The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?

The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?

Journal: Cancers

Published: October 08, 2025

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

Journal: European journal of haematology

Published: September 27, 2025

Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti- CD38 monoclonal antibodies: outcomes from a real-world experience.

Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti- CD38 monoclonal antibodies: outcomes from a real-world experience.

Journal: Haematologica

Published: September 15, 2025

Belamaf: is renal toxicity an overlooked side effect?

Belamaf: is renal toxicity an overlooked side effect?

Journal: Blood advances

Published: September 09, 2025

Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients.

Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 13, 2025

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape.

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape.

Journal: ESMO open

Published: July 11, 2025

Showing 1-12 of 184

Last Updated: 09/26/2026